Finally, A REMS FDA Could Live With
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
"It took us three months" to negotiate with FDA on the fine points of the REMS and make the refinements required to finalize the document, Amgen safety exec Rekha Garg told the recent Post-Approval Summit at Harvard.